Dr. Roberto A. Cano, MD

Dr. Cano practices at Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami.

Dr. Cano's NPI, 1164488110, was assigned on April 26, 2006. Dr. Cano graduated from Tulane School of Medicine in 1980. Dr. Cano holds Florida license ME55231.

Dr. Cano's primary practice is Sylvester Comprehensive Cancer Center, at 1475 Nw 12th Ave, Miami, FL 33136.

Dr. Cano's primary practice is Sylvester Comprehensive Cancer Center in Miami, Florida, part of University of Miami. The medical group on file is University of Miami Health System.

Dmand AI tracks the electronic health record (EHR) system at each site where Dr. Cano practices. Vendor and product names are available with a free account.

Internal medicine is Dr. Cano's primary specialty in the NPI Registry, under taxonomy code 207R00000X. Dr. Cano is board certified in hematology by the American Board of Internal Medicine. Dr. Cano is licensed in Florida.

Dmand AI lists acute kidney failure, chronic anemia, chronic kidney disease, deep vein thrombosis (DVT), gastroduodenitis, immune deficiency disease, menopause and muscle pain, fibromyalgia, and limb pain among the conditions Dr. Cano treats.

CMS data shows 280 Medicare services from Dr. Cano across 3 procedure codes in 2024, all of them office visits, for 104 Medicare patients. Medicare paid $24,896 for them. Every service was in an office.

CMS counts 104 Medicare patients who saw Dr. Cano in 2024. The largest group is 65 to 74, with 51 patients. 75% of them have high blood pressure, and 75% have high cholesterol. 27% are also on Medicaid. Their average risk score is 2.20, where 1.00 is the Medicare average, so they are sicker than most Medicare patients.

Across all payers, Dmand AI patient panel data puts Dr. Cano's median patient age at 62, with 58% women.

In 2024, Dr. Cano wrote 265 Medicare Part D claims for 48 patients. 50% of them were for generic drugs. CMS names the drug for 150 of them, across 9 drugs with 11 or more claims each, at $722,948 in total drug cost. In 2023, CMS named 241 claims across 14 drugs.

CMS publishes a Merit-based Incentive Payment System (MIPS) score of 88 out of 100 for Dr. Cano for performance year 2024, reported as part of a group. Dr. Cano accepts Medicare assignment, so Medicare's approved amount is taken as full payment. CMS lists Dr. Cano as offering telehealth.

Dmand AI links 1 paper to Dr. Cano. Dr. Cano's most frequent co-authors are Rogerio Cezar Lilenbaum, MD and Jose Lutzky, MD.

CMS Open Payments shows 145 general payments to Dr. Cano from 30 drug and device companies from 2016 to 2025. Food and beverage make up the largest share, 84% of the total. Janssen Pharmaceuticals, Inc paid the most, $761.

Dr. Cano graduated from Tulane School of Medicine in 1980. Dr. Cano is a member of ASCO.

Dr. Cano is in network with 12 carriers, including Aetna, Elevance and Excellus BlueCross BlueShield. PPO plans come from the most carriers, 8. Check the plan with the practice before a visit.